Examine the Ophthalmic Pharmaceuticals Market

March 16th, 2009

   2009 MAR 16 -- Reportlinker.com announces that a new market research report is available in its catalogue. Ophthalmic Pharmaceuticals, Market Analysis, Forecasts and Dynamics - 2009-2023 http://www.reportlinker.com/p0109127/Ophthalmic-Pharmaceuticals-Market-Analysis-Forecasts-and-Dynamics---2009-2023.html The global market for ophthalmic pharmaceuticals is a large and profitable segment of the healthcare market, with ophthalmic sales of over $10bn in 2007. The recent therapeutic and commercial success of Lucentis has increased the number of blockbuster ophthalmic drugs and highlighted the lucrative commercial rewards on offer in this sector. Which will be the blockbusters of the future? This cutting-edge report provides the answer – and other essential information that you need to understand the ophthalmic pharmaceutical sector. 'In 15 years, I expect there will be one or more neuroprotective drugs on the market,' says a leading expert, interviewed for this report - Ophthalmic Pharmaceuticals, 2009-2023.

   The report identifies these future blockbuster drugs and goes on to reveal two currently-untreatable or recalcitrant therapeutic areas with significant unmet need and greatest potential for market growth. Ophthalmic Pharmaceuticals, 2009-2023 - provides an in-depth analysis of the ophthalmic market, using a wealth of research tools - including sales forecasting, qualitative analyses, probing interviews with industry experts, literature searches and use of commercial databases. The report is packed with original data in tables, charts and other formats. It is predicted that the global ophthalmic pharmaceutical market will grow steadily from 2009-2023, driven by increasing prevalence of ophthalmic disorders amongst an expanding population of older people. In some countries the market will expand rapidly in coming years, whilst in others the market will stagnate. By purchasing this report, you will find out by how much the ophthalmic market will grow and which countries will achieve most rapid sales growth. Highlights of Ophthalmic Pharmaceuticals, 2009-2023 include: • Forecasts for the global ophthalmic market, key therapeutic categories and leading brands from 2009 to 2023

   • Expert opinion from key-opinion leaders in the ophthalmic pharmaceutical sector

   • Examination of strengths, weakness, opportunities and threats (SWOT) facing major stakeholders in that industrial sector

   • In-depth analysis of the ophthalmic pharmaceutical pipeline

   • Analysis and forecasts for the principal national markets, including the US, Japan, Brazil, India, China and leading European markets. Why you should buy this report: • To receive a comprehensive analysis of the prospects for ophthalmic drugs, including key metrics and predicted revenues, by therapeutic category and brand

   • To discover the forces, restraints, competition and opportunities influencing each of the separate ophthalmic markets, including anti-glaucoma, retinal disorder, dry eye and ophthalmic allergy, inflammation and infection

   • To read the views of experts in the industry, regarding current and future trends, opportunities and drivers. The report includes full transcripts of interviews – information that you will not find anywhere else

   • To find out how the ophthalmic pharmaceutical market is progressing worldwide - both technologically and commercially This report provides a comprehensive pipeline analysis showing how a range of drugs - from simple anti-infective agents to advanced molecular treatments – combined with a wider range of drug delivery systems should aid the restoration of vision or the cessation of vision loss. Success in the ophthalmic pharmaceutical market from 2008 to 2023 will be characterised by the launch of products with superior efficacy, safety and tolerability.

   Ophthalmic Pharmaceuticals, 2009-2023 shows how emerging technologies that increase clinical effectiveness and/or increase patient compliance will be particularly important therapeutically and commercially.

   1 Executive Summary

   2 Ophthalmic Disorders and Treatments

   2.1 The Ophthalmology Market

   2.2 Ophthalmic Disorders

   2.3 The Human Eye and the Vision Process

   2.4 Glaucoma

   2.4.1 Primary Open Angle Glaucoma: The Most Common Type of Glaucoma

   2.4.2 Closed Angle Glaucoma

   2.4.3 Secondary Glaucoma

   2.4.4 Congenital Glaucoma

   2.4.5 Normal Tension Glaucoma

   2.4.6 Ocular Hypertension

   2.4.7 Glaucoma Risk Factors

   2.4.8 Diagnosis of Glaucoma

   2.4.9 Prevalence of Glaucoma

   2.4.10 Treatment of Glaucoma

   2.4.11 Prostaglandins are the First-Line Treatment of Choice

   2.4.12 Second-Line Glaucoma Treatments

   2.4.13 Combination Treatments

   2.4.14 Laser Treatment

   2.4.15 Surgery (Trabeculectomy)

   2.5 Age-Related Macular Degeneration (AMD)

   2.5.1 Dry AMD

   2.5.2 Wet AMD

   2.5.3 AMD Risk Factors

   2.5.4 Diagnosis of AMD

   2.5.5 Prevalence of AMD

   2.5.6 Treatment of AMD

   2.6 Diabetic Retinopathy

   2.6.1 Diagnosis of Diabetic Retinopathy

   2.6.2 Prevalence of Diabetic Retinopathy

   2.6.3 Laser and Surgical Treatments are the Main Treatments for Diabetic Retinopathy

   2.6.4 Pharmaceutical Treatments

   2.7 Ophthalmic Allergies

   2.7.1 Allergic Conjunctivitis is the Most Common Eye Allergy

   2.7.2 Ophthalmic Allergy Treatments

   2.8 Ophthalmic Inflammatory Disorders

   2.8.1 Uveitis is the Most Common Ocular Inflammatory Disease

   2.8.2 Ophthalmic Inflammatory Drugs

   2.9 Ophthalmic Infections

   2.9.1 Types of Eye Infection

   2.9.2 Treatment of Eye Infections

   2.10 Dry Eye Syndrome

   2.10.1 Causes and Prevalence of Dry Eye Syndrome

   2.10.2 The Mainstay of Dry Eye Treatment is Artificial Tears

   2.10.3 Prescription-Only Drugs for Dry Eye are Limited

   2.10.4 Tear Augmenters (Punctal Plugs)

   3 The Global Ophthalmic Pharmaceutical Market, 2008-2023

   3.1 The Ophthalmic Pharmaceutical Market in 2007

   3.1.1 Anti-Glaucoma had Largest Market Share in 2007

   3.1.2 Top Twelve Ophthalmic Pharmaceutical Brands, 2007

   3.1.3 Three Manufacturers Account for Almost Half the Market

   3.2 Global Ophthalmic Pharmaceutical Market Forecasts, 2008-2023

   3.2.1 Generic Competition in the Ophthalmic Pharmaceutical Market during 2008-2013

   3.2.2 What are the Prospects for the Ophthalmic Pharmaceutical Market during 2013-2023?

   3.3 Ophthalmic Pharmaceutical Therapeutic Category Market Forecasts, 2008-2023

   3.3.1 Two Therapeutic Categories Will Power Growth during 2008-2013

   3.3.2 Retinal Disorder Drug Growth Will Continue Through 2013-2018

   3.3.3 High Growth and Return to Market-Leading Position for Anti-Glaucoma during 2018-2023

   4 The Anti-Glaucoma Market, 2008-2023

   4.1 The Anti-Glaucoma Market in 2007

   4.1.1 Prostaglandin Analogues Lead the Anti-Glaucoma Market in 2007

   4.1.2 Xalatan/Xalacom

   4.1.3 Cosopt/Trusopt

   4.1.4 Travatan/Travatan Z/DuoTrav

   4.1.5 Lumigan/Ganfort

   4.1.6 Alphagan/Combigan

   4.1.7 Azopt

   4.2 Anti-Glaucoma Market Forecasts, 2008-2023

   4.2.1 Generic Competition Will Impact Anti-Glaucoma Market During 2008-2013

   4.2.2 Novel Glaucoma Drugs Will Drive Growth during 2013-2023

   4.2.3 Xalatan/Xalacom Sales Forecast, 2008-2023

   4.2.4 Cosopt/Trusopt Sales Forecast, 2008-2023

   4.2.5 Travatan/Travatan Z/DuoTrav Sales Forecast, 2008-2023

   4.2.6 Lumigan/Ganfort Sales Forecast, 2008-2023

   4.2.7 Alphagan/Combigan Sales Forecast, 2008-2023

   4.2.8 Azopt/Azarga Sales Forecast, 2008-2023

   5 The Ophthalmic Anti-Allergy/Inflammatory/Infective Market, 2008-2023

   5.1 The Ophthalmic Anti-Allergy/Inflammatory/Infective Market in 2007

   5.1.1 Patanol/Opatanol/Pataday

   5.1.2 TobraDex

   5.1.3 Vigamox/Vegamox

   5.2 Ophthalmic Anti-Allergy/Inflammatory/Infective Market Forecasts, 2008-2023

   5.2.1 Lack of Novel Pipeline Products in Anti-Allergy/Inflammatory/Infective Sector

   5.2.2 Patanol/Opatanol/Pataday Sales Forecast, 2008-2023

   5.2.3 TobraDex Sales Forecast, 2008-2023

   5.2.4 Vigamox/Vegamox Sales Forecast, 2008-2023

   6 The Retinal Disorder Market, 2008-2023

   6.1 The Retinal Disorder Market in 2007

   6.1.1 Wet AMD has the Largest Market Share of the Retinal Disorder Market

   6.1.2 Lucentis Took Control of the Retinal Disorder Market in 2007

   6.1.3 Visudyne was the Second Highest-Selling Retinal Disorder Drug in 2007

   6.1.4 Lucentis has Side-Lined Macugen but Faces Potent Threat from Avastin

   6.1.5 The Diabetic Retinopathy Market

   6.2 Retinal Disorder Market Forecasts, 2008-2023

   6.2.1 Lucentis Will Drive the Retinal Disorder Market during 2008-2013

   6.2.2 Novel Drugs and New Disease Treatments will Drive Growth during 2013-2023

   6.2.3 Lucentis Sales Forecast, 2008-2023

   6.2.4 Visudyne Sales Forecast, 2008-2023

   7 The Dry Eye Market, 2008-2023

   7.1 The Dry Eye Market in 2007

   7.1.1 Restasis is the Only Prescription-Only Drug for Dry Eye in the US

   7.1.2 Hyalein: Marketed in Japan and China

   7.1.3 The OTC Market for Artificial Tears is Fragmented and Competitive

   7.2 Dry Eye Market Forecasts, 2008-2023

   7.2.1 Increased Sales of Dry Eye Prescription Drugs Forecasted During 2008-2013

   7.2.2 Growth in the Dry Eye Market Will Moderate After 2013

   7.2.3 Restasis Sales Forecast, 2008-2023

   8 Issues Affecting the Market for Ophthalmic Pharmaceuticals

   8.1 SWOT Analysis of the Ophthalmic Pharmaceutical Market

   8.2 Strengths in the Ophthalmic Pharmaceutical Market

   8.2.1 Development of New Drug Delivery Methods and Formulations

   8.2.2 Intraocular Injections

   8.2.3 Sustained-Release Ocular Implants

   8.2.4 Gene Therapy and RNA Interference Technology

   8.2.5 New Ophthalmic Therapeutic Applications for Drugs

   8.2.6 Development of Neuroprotective Anti-Glaucoma Medications

   8.3 Weaknesses in the Ophthalmic Pharmaceutical Market

   8.3.1 The Ophthalmic Pharmaceutical Market Will Face Generic Competition

   8.3.2 Avastin is Cannibalising Lucentis’ Revenues

   8.4 Opportunities for the Ophthalmic Pharmaceutical Market

   8.4.1 The Greying of the World Population

   8.4.2 Increasing Prevalence of Diabetes and Unhealthy Lifestyles

   8.4.3 Increasing Prevalence of Eye Disorders

   8.4.4 Retinal Disorders Will Have the Most Marked Increases in Prevalence

   8.4.5 Increasing Prevalence of Glaucoma, Dry Eye and Other Ophthalmic Disorders

   8.4.6 Generous Reimbursement for Ophthalmic Pharmaceuticals

   8.5 Threats Facing the Ophthalmic Pharmaceutical Market

   8.5.1 Poor Patient Compliance

   8.5.2 The Rate of Diagnosis for Eye Disorders is Low

   9 Ophthalmic Pharmaceutical Country Markets

   9.1 Leading Ophthalmic Pharmaceutical Country Markets, 2007

   9.2 Leading Developed Country Ophthalmic Pharmaceutical Markets, 2008-2023

   9.2.1 The US Ophthalmic Pharmaceutical Market

   9.2.2 The Japanese Ophthalmic Pharmaceutical Market

   9.2.3 European Ophthalmic Pharmaceutical Markets

   9.3 Emerging Economy Ophthalmic Pharmaceutical Market Forecasts, 2008-2023

   9.3.1 Ophthalmic Pharmaceuticals are Making the Leap to Developing Countries

   9.3.2 The Indian Ophthalmic Pharmaceutical Market

   9.3.3 The Chinese Ophthalmic Pharmaceutical Market

   10 The Ophthalmic Pharmaceutical Pipeline

   10.1 The Ophthalmic Pharmaceutical Pipeline: Richest in Anti-Glaucoma and Retinal Disorder Drugs

   10.2 The Anti-Glaucoma Pipeline

   10.2.1 Neuroprotection Will Be the Most Important Anti-Glaucoma Pipeline Development

   10.2.2 Taflotan/DE-085 (Santen/Asahi)

   10.2.3 Azarga (Alcon)

   10.2.4 Anecortave (Alcon)

   10.2.5 DNB-001 (Danube)

   10.2.6 BVT.28949 (Biovitrum)

   10.2.7 DE-092/Olmesarten (Santen)

   10.2.8 OT-730 (Othera)

   10.2.9 AL-37807 (Alcon)

   10.2.10 PF-4217329 (Pfizer)

   10.2.11 QLT’s Punctal Plug Delivery Technology

   10.2.12 PF-03187207 (NicOx/Pfizer)

   10.3 The Ophthalmic Anti-Allergy Pipeline

   10.3.1 Bepreve (ISTA/Senju)

   10.3.2 FOV1101 (Fovea/CombinatoRx)

   10.3.3 DE-103 (Santen)

   10.4 The Ophthalmic Anti-Inflammatory Pipeline

   10.4.1 T-Pred (ISTA)

   10.4.2 AzaSite Plus/ASV-502 (InSite Vision)

   10.4.3 Durezol (Senju/Sirion Therapeutics)

   10.4.4 Luveniq (LuxBiosciences)

   10.4.5 Simulect (Cerimon)

   10.4.6 EGP-437 (EyeGatePharm)

   10.5 The Ophthalmic Anti-Infective Pipeline

   10.5.1 TobraDex ST (Alcon)

   10.5.2 ISV-403 (Besifloxacin, Bausch & Lomb)

   10.5.3 Moxifloxacin/Dexamethasone (Alcon)

   10.6 The Retinal Disease Pipeline

   10.6.1 Retinal Diseases Have the Richest Pipeline

   10.6.2 Arxxant (Eli Lilly/Alcon/Takeda)

   10.6.3 Vitrase/Vitragen (ISTA)

   10.6.4 Aflibercept/VEGF Trap-Eye (Regeneron/Bayer)

   10.6.5 Bevasiranib/Cand5 (Opko)

   10.6.6 Lucentis (Genentech/Roche/Novartis)

   10.6.7 Atacand/TCV-116 (AstraZeneca/Takeda)

   10.6.8 SNK-860 (Sanwa Kagaku Kenkyusho)

   10.6.9 Posurdex/SK-0503 (Allergan/Sanwa Kagaku Kenkyusho)

   10.6.10 Medidur (pSivida/Alimera Sciences/Pfizer)

   10.6.11 NT-501 (Neurotech)

   10.6.12 Microplasmin (ThromboGenics)

   10.6.13 Sustained-Release Brimonidine (Allergan)

   10.6.14 RTP801i-14/PF-4523655 (Quark/Pfizer)

   10.6.15 AGN-745/SIRNA-027 (Allergan/Merck & Co.)

   10.6.16 ATG-3 (CoMentis)

   10.6.17 OT-551 (Othera)

   10.6.18 Fenretinide (Sirion Therapeutics)

   10.6.19 RPE65 Gene Therapy (Targeted Genetics)

   10.7 The Dry Eye Pipeline

   10.7.1 Prolacria (Inspire/Allergan/Santen)

   10.7.2 Cyclosporine Ophthalmic Solution (Sirion Therapeutics)

   10.7.3 Rebamipide (Otsuka/Acucela)

   10.7.4 DE-101/Rivoglitazone (Santen)

   10.7.5 Ecabet (ISTA)

   10.8 The Pipeline for Other Ophthalmic Indications Includes Eyelash Growth-Stimulators

   11 Expert Views from Key-Opinion Leaders

   11.1 Barrett Katz, M.D., M.B.A., Chief Executive Officer and Chief Medical Officer and Brian Levy, O.D., M.Sc., Chief Operating Officer, Danube Pharmaceuticals

   11.1.1 Neuroprotection is the Key Unmet Need Amongst Glaucoma Patients

   11.1.2 Danube’s Pipeline Anti-Glaucoma Medication: DNB-001

   11.1.3 Key Threats Facing the Ophthalmic Pharmaceutical Industry

   11.1.4 Major Growth Opportunities in the Ophthalmic Pharmaceutical Industry

   11.1.5 The Future of the Anti-Glaucoma Market

   11.2 Dr Al Reaves, Ph.D., Senior Vice President of Clinical Development, Othera Pharmaceuticals

   11.2.1 Which Areas of the Ophthalmic Pharmaceutical Industry will have Greatest Growth?

   11.2.2 Othera’s Geographic Atrophy Drug: OT-551

   11.2.3 How Will Glaucoma be Treated in 2023?

   11.2.4 Othera’s Neuroprotective Anti-Glaucoma Drug: OT-440

   11.2.5 Othera’s New Generation Beta Blocker: OT-730

   11.2.6 New Drugs for Ophthalmic Conditions Currently with No Treatments

   12 Conclusions

   12.1 The Ophthalmic Pharmaceutical Market in 2007

   12.2 Visiongain’s Ophthalmic Pharmaceutical Market Forecast, 2008-2023

   12.3 Who Will Succeed in the Ophthalmic Pharmaceutical Marketplace?

   12.4 Where Will the Ophthalmic Pharmaceutical Market Grow Fastest?

   List of Tables

   Table 2.1 Major Glaucoma Pharmaceutical Types

   Table 2.2 Major AMD Drugs

   Table 2.3 Ophthalmic Allergy Drug Types

   Table 2.4 Ophthalmic Inflammatory Disorder Drug Types

   Table 2.5 Key Ophthalmic Anti-Infective Drug Types

   Table 3.1 Ophthalmic Pharmaceutical Therapeutic Category Market Share, 2007

   Table 3.2 Top-Twelve Ophthalmic Pharmaceutical Brands, 2007

   Table 3.3 Top-Eight Ophthalmic Pharmaceutical Manufacturers, 2007

   Table 3.4 Global Ophthalmic Pharmaceutical Market Forecast, 2008-2013

   Table 3.5 Global Ophthalmic Pharmaceutical Market Forecast, 2014-2023

   Table 3.6 Ophthalmic Pharmaceutical Therapeutic Category Forecast, 2008-2013

   Table 3.7 Ophthalmic Pharmaceutical Therapeutic Category Forecast, 2014-2023

   Table 4.1 Leading Anti-Glaucoma Brands, 2007

   Table 4.2 World Anti-Glaucoma Market Forecast, 2008-2013

   Table 4.3 World Anti-Glaucoma Market Forecast, 2014-2023

   Table 4.4 Leading Anti-Glaucoma Brands Sales Forecast, 2008-2013

   Table 4.5 Leading Anti-Glaucoma Brands Sales Forecast, 2014-2023

   Table 5.1 Therapeutic Category Market Share in the Ophthalmic Anti-Allergy/Inflammatory/Infective Market, 2007

   Table 5.2 Leading Anti-Allergy/Inflammatory/Infective Brands, 2007

   Table 5.3 Ophthalmic Anti-Allergy/Inflammatory/Infective Market Forecast, 2008-2013

   Table 5.4 Ophthalmic Anti-Allergy/Inflammatory/Infective Market Forecast, 2014-2023

   Table 5.5 Leading Anti-Allergy/Inflammatory/Infective Brand Sales Forecast, 2008-2013

   Table 5.6 Leading Anti-Allergy/Inflammatory/Infective Brand Sales Forecast, 2014-2023

   Table 6.1 Therapeutic Category Market Share in the Retinal Disorder Market, 2007

   Table 6.2 Leading Retinal Disorder Brands, 2007

   Table 6.3 World Retinal Disorder Market Forecast, 2008-2013

   Table 6.4 World Retinal Disorder Market Forecast, 2014-2023

   Table 6.5 Leading Retinal Disorder Brands Sales Forecast, 2008-2013

   Table 6.6 Leading Retinal Disorder Brands Sales Forecast, 2014-2023

   Table 7.1 Leading Dry Eye Brands, 2007

   Table 7.2 World Dry Eye Market Forecast, 2008-2013

   Table 7.3 World Dry Eye Market Forecast, 2014-2023

   Table 7.4 Restasis Sales Forecast, 2008-2013

   Table 7.5 Restasis Sales Forecast, 2014-2023

   Table 8.1 SWOT Chart for the Ophthalmic Pharmaceutical Market

   Table 8.2 Expected Patent Expiries for Leading Ophthalmic Pharmaceuticals, 2008-2014

   Table 8.3 Global Ophthalmic Disorder Prevalence Forecast, 2007-2030

   Table 9.1 Leading Ophthalmic Pharmaceutical Country Markets, 2007

   Table 9.2 Leading Ophthalmic Pharmaceutical Country Market Forecasts, 2008-2013

   Table 9.3 Leading Ophthalmic Pharmaceutical Country Market Forecasts, 2014-2023

   Table 10.1 Key Drugs in the Anti-Glaucoma Pipeline

   Table 10.2 Key Drugs in the Ophthalmic Anti-Allergy Pipeline

   Table 10.3 Key Drugs in the Ophthalmic Anti-Inflammatory Pipeline

   Table 10.4 Key Drugs in the Ophthalmic Anti-Infective Pipeline

   Table 10.5 Key Drugs in the Retinal Disease Pipeline: 1

   Table 10.6 Key Drugs in the Retinal Disease Pipeline: 2

   Table 10.7 Key Drugs in the Dry Eye Pipeline

   Table 10.8 Key Pipeline Drugs for Other Ophthalmic Indications

   List of Figures

   Figure 3.1 Ophthalmic Pharmaceutical Therapeutic Category Market Share, 2007

   Figure 3.2 Top-Eight Ophthalmic Pharmaceutical Manufacturers, 2007

   Figure 3.3 Global Ophthalmic Pharmaceutical Market Forecast, 2008-2023

   Figure 3.4 Ophthalmic Pharmaceutical Therapeutic Category Market Share and Forecast, 2008-2023

   Figure 3.5 Ophthalmic Pharmaceutical Therapeutic Category Forecast, 2008-2023

   Figure 4.1 Leading Anti-Glaucoma Brands, 2007

   Figure 4.2 World Anti-Glaucoma Market Forecast, 2008-2023

   Figure 4.3 Leading Anti-Glaucoma Brands, 2013

   Figure 4.4 Xalatan/Xalacom Sales Forecast, 2008-2023

   Figure 4.5 Cosopt/Trusopt Sales Forecast, 2008-2023

   Figure 4.6 Travatan/Travatan Z/DuoTrav Sales Forecast, 2008-2023

   Figure 4.7 Lumigan/Ganfort Sales Forecast, 2008-2023

   Figure 4.8 Alphagan/Combigan Sales Forecast, 2008-2023

   Figure 4.9 Azopt/Azarga Sales Forecast, 2008-2023

   Figure 5.1 Therapeutic Category Market Share in the Ophthalmic Anti-Allergy/Inflammatory/Infective Market, 2007

   Figure 5.2 Ophthalmic Anti-Allergy/Inflammatory/Infective Market Forecast, 2008-2023

   Figure 5.3 Patanol/Opatanol/Pataday Sales Forecast, 2008-2023

   Figure 5.4 TobraDex Sales Forecast, 2008-2023

   Figure 5.5 Vigamox/Vegamox Sales Forecast, 2008-2023

   Figure 6.1 Therapeutic Category Market Share in the Retinal Disorder Market, 2007

   Figure 6.2 Leading Retinal Disorder Brands, 2007

   Figure 6.3 World Retinal Disorder Market Forecast, 2008-2023

   Figure 6.4 Lucentis Sales Forecast, 2008-2023

   Figure 6.5 Visudyne Sales Forecast, 2008-2023

   Figure 7.1 World Dry Eye Market Forecast, 2008-2023

   Figure 7.2 Restasis Sales Forecast, 2008-2023

   Figure 8.1 Global Population Aged Over 65, 2007-2023

   Figure 8.2 Population Aged 65 Years or Over in Major Ophthalmic Pharmaceutical Country Markets, 2007 and 2023

   Figure 8.3 Global Prevalence of Diabetes and Diabetic Retinopathy, 2007 and 2030

   Figure 9.1 Leading Ophthalmic Pharmaceutical Country Markets, 2007

   Figure 9.2 Leading Ophthalmic Pharmaceutical Country Markets, 2013

   Figure 9.3 Leading Ophthalmic Pharmaceutical Country Markets, 2018

   Figure 9.4 Leading Ophthalmic Pharmaceutical Country Markets, 2023

   Figure 9.5 US and Japanese Ophthalmic Pharmaceutical Market Forecasts, 2008-2023

   Figure 9.6 European, Brazilian, Indian and Chinese Ophthalmic Pharmaceutical Market Forecasts, 2008-2023

   Figure 12.1 Global Ophthalmic Pharmaceutical Market Forecast, 2008-2023

   Companies Listed

   Acucela

   Alcon (Nestle)

   Alimera Sciences

   Allergan

   American Academy of Ophthalmology (AAO) [US]

   American Society of Retinal Specialists (ASRS) [US]

   Asahi

   AstraZeneca

   Bausch & Lomb

   Bayer

   Biovitrum

   Can-Fite

   Cerimon

   Chugai

   CombinatoRx

   CoMentis

   Danube

   Eli Lilly

   Esteve

   European Medicines Agency (EMEA)

   EyeGate

   Food and Drug Administration (FDA) [US]

   Fovea

   Genentech

   GSK

   InSite Vision

   Inspire

   ISTA Pharmaceuticals

   Kowa

   Kyowa Hakko Kirin

   Laborotorios Sophia [Mexico]

   LEO Pharma

   LuxBiosciences

   Meda

   Merck & Co.

   Ministry of Health, Labour and Welfare [Japan]

   Moorfields Eye Hospital [UK]

   National Eye Institute (NEI) [US]

   National Institute for Health and Clinical Excellence (NICE) [UK]

   National Institutes of Health (NIH) [US]

   Neurotech

   NicOx

   Novartis

   Opko

   OSI Pharmaceuticals

   Othera

   Otsuka

   Pfizer

   pSivida

   QLT

   Quark

   Regeneron

   Roche

   Santen

   Sanwa Kagaku Kenkyusho

   Senju

   Sirion Therapeutics

   Takeda

   Targeted Genetics

   ThromboGenics

   University College of London's (UCL) Institute of Ophthalmology [UK] To order this report: Ophthalmic Pharmaceuticals, Market Analysis, Forecasts and Dynamics - 2009-2023 http://www.reportlinker.com/p0109127/Ophthalmic-Pharmaceuticals-Market-Analysis-Forecasts-and-Dynamics---2009-2023.html More market research reports here!

   Keywords: Age-Related Macular Degeneration, Allergic Conjunctivitis, Allergic Disease, Allergies, Allergy Medicine, Alphagan, Anti-Infectives, Avastin, Azopt, Bevacizumab, Bimatoprost, Biotechnology, Brimonidine Tartrate, Brinzolamide, Congenital Glaucoma, Cosopt, Cyclosporine, Dexamethasone, Diabetes, Diabetic Retinopathy, Dorzolamide Hydrochloride, Drug Delivery, Drug Development, Drugs, Dry Eye Syndrome, Endocrinology, Eye Infections, Gene Therapy, Genetics, Genomics, Inflammation, Latanoprost, Lumigan, Macugen, Macular Degeneration, Medical Device, Moxifloxacin Hydrochloride, Ocular Hypertension, Olopatadine Hydrochloride, Open-Angle Glaucoma, Ophthalmology, Patanol, Pegaptanib Sodium, Pharmaceuticals, Pulmonology, RNA Research, Restasis, Surgery, Timolol Maleate, Tobradex, Tobramycin, Trabeculectomy, Travatan, Travoprost, Treatment, Trusopt, Uveitis, Verteporfin, Vigamox, Visudyne, Xalatan, ReportLinker.

   This article was prepared by Pain & Central Nervous System Week editors from staff and other reports. Copyright 2009, Pain & Central Nervous System Week via NewsRx.com.

Return to Medical Devices Alert Section


	Home \| Free Newsletters \| Products \| Article Library \| About Us \| Contact \| Privacy Policy \| Search \| Visit VerticalNews.com Copyright © 2009 NewsRx